NEOPHARMA NUTSHELL COMMUNITY

“𝗠𝘆 𝗱𝗮𝗱 𝗶𝘀 𝟳𝟬 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝘆 — 𝘀𝗵𝗼𝘂𝗹𝗱 𝗵𝗲 𝘀𝘁𝗮𝗿𝘁 𝗮𝘀𝗽𝗶𝗿𝗶𝗻 𝘁𝗼 𝗽𝗿𝗲𝘃𝗲𝗻𝘁 𝘀𝘁𝗿𝗼𝗸𝗲?” “𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗲𝘅𝗲𝗿𝗰𝗶𝘀𝗲 𝗱𝗼 𝗜 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗻𝗲𝗲𝗱?” “𝗜 𝗵𝗮𝘃𝗲 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 — 𝗱𝗼𝗲𝘀 𝗺𝘆 𝗔𝟭𝗰 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗯𝗲 𝟲.𝟱?” “𝗔𝗿𝗲 𝗚𝗟𝗣-𝟭 𝗱𝗿𝘂𝗴𝘀 𝗿𝗲𝗮𝗹𝗹𝘆 𝗴𝗼𝗼𝗱 𝗳𝗼𝗿 𝘀𝘁𝗿𝗼𝗸𝗲 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻?” “𝗪𝗵𝗮𝘁 𝗲𝘅𝗮𝗰𝘁𝗹𝘆 𝗶𝘀 𝘁𝗵𝗲 𝗠𝗲𝗱𝗶𝘁𝗲𝗿𝗿𝗮𝗻𝗲𝗮𝗻 𝗱𝗶𝗲𝘁?” These questions come up daily — in clinic, on rounds, and at the bedside. 🔑 𝗞𝗲𝘆 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲-𝗯𝗮𝘀𝗲𝗱 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: • Aspirin is NOT beneficial for primary prevention in adults ≥70 • ≥150 min/week of moderate activity lowers stroke risk (Moderate means HR increased 50-60%, or in other words, you can talk but not sing) • Intensive glycemic control (A1c ≤6.5%) increase risk of hypoglycemia compared with < 7, with no proven stroke benefits. • Yes, GLP-1 receptor agonists reduce stroke in type 2 diab...

  For decades, animal models have powered early drug development. But a quiet shift is underway. Human relevant microphysiological systems, known as organs on chips, are beginning to influence how we predict drug safety and efficacy. This is no longer experimental. The global organ on chip market is estimated at roughly 100 to 200 million USD today and is projected to cross nearly 1 billion within the next decade, signaling strong industry adoption. Several companies are already shaping this space: • Emulate is widely recognized for commercial lung, liver, brain, and intestine chips used in toxicology and disease modeling.  Emulate • MIMETAS developed the OrganoPlate platform, enabling higher throughput screening compatible with pharma workflows.  MIMETAS • CN Bio built PhysioMimix systems that support liver and multi organ interaction studies.  PhysioMimix • Hesperos is advancing interconnected “human on a chip” models designed to simulate systemic drug responses....

  AI is no longer optional in pharma. It is becoming a core skill. From drug discovery and ADMET modeling to clinical trial optimization and compliance, AI is reshaping how we develop, test, and deliver medicines. If you are a B.Pharm, M.Pharm, PharmD, or Life Sciences student, this is the right time to build AI capability alongside your domain knowledge. Here are some valuable certifications and platforms to explore in 2026: • University-led AI in Pharmacy programs • MIT Sloan programs focused on AI in Biotech and decision making • IIT Kanpur and NPTEL courses in AI for healthcare and drug discovery • Hands-on platforms like Biotecnika for Python and bioactivity projects • Industry certifications from ASHP and AI Certs The goal is not to become a data scientist overnight. The goal is to become a pharma professional who understands AI. Pharma + AI = Future-ready profile. If you are planning to upskill this year, which area are you targeting? Drug discovery, clinical research, regul...